A Northwestern Medicine study published in Nature Communications has revealed how HIV can protect infected cells by altering the sugars on their surface, hindering the host immune system and avoiding ...

Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...

Advancements in HIV/AIDS research, drug development, and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check ...

Dec 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling drug Biktarvy in a late-stage ...

I’ve spent much of my career caring for people in places most Americans never see. I’ve worked in refugee camps, on the streets of large cities, in rural communities cut off from care, in clinics ...

New York City health department officials are concerned after recently released data showed a slight uptick in HIV cases – which comes as the federal government proposes cutting funding to HIV ...

On World AIDS Day, advocates warn federal cuts could reverse progress. Carole Treston had been a nurse early in her career when she and her mother traveled to Washington, D.C., and saw the AIDS ...

A man has become the seventh person to be left HIV-free after receiving a stem cell transplant to treat blood cancer. Significantly, he is also the second of the seven who received stem cells that ...

A new study from UC San Francisco shows it may be possible to control HIV without long-term antiviral treatment — an advance that points the way toward a possible cure for a disease that affects 40 ...

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval molecule as a new anchor treatment for the infectious disease. Integrase strand ...